Post Doc – Neuroblastoma Research, Children’s Hospital of Philadelphia

  • Postdoc
  • Developing targeted and immune-therapies for childhood cancers.
  • Applications have closed
Lab Website: yael-mosse-laboratory

Philadelphia, PA


Description:

Seeking bright and motivated postdoctoral fellow to work under Yael P. Mossé, MD as part of a growing, multidisciplinary team that she oversees, focused on developing targeted and immune-therapies for childhood cancers. The postdoc will work as part of a highly collaborative team, both at Penn/CHOP and institutions across North America. Our research is focused on neuroblastoma, a common and often devastating childhood cancer of the peripheral nervous system. This position has two central projects, both focused on therapeutic targeting of the dominant oncogenes driving the growth of neuroblastoma: MYCN and ALK.
-
Amplification of the MYCN oncogene is present in over 40% of high-risk neuroblastomas, and many high-risk neuroblastomas without MYCN amplification show overexpressed MYC protein. Therapeutic targeting of MYC(N) proteins directly remains challenging. MYC family proteins are small basic helix-loop-helix transcription factors with an inherently unstructured N-terminus and no known binding pockets for small molecular interactions. That said, it is now clear that these proteins coordinate complex protein interactomes that likely vary by cellular, spatial and temporal contexts. Advances in structural biology and medicinal chemistry now allow an unprecedented opportunity to drug these previously undruggable oncoproteins. The objective of this multi-institution project is to develop drugs that will directly degrade and/or destabilize the MYCN oncoprotein in pediatric cancer models, and to provide preclinical proof-of-concept to bring these compounds to clinical trials.
-
Our discovery of gain-of-function mutations in ALK as the genetic etiology of familial NB provided the impetus for this second project. Moreover, these same mutations are the most frequent somatic single nucleotide mutation in this disease and have been shown to act as oncogenic drivers by promoting ligand-independent ALK tyrosine kinase activity. This project is focused on the development of highly specific antibody-based approaches to target cell surface anaplastic lymphoma kinase oncogene (ALK) on neuroblastomas and other ALK-expressing pediatric cancers.
-
These are both high-impact projects and there is the possibility of taking on one of the two proposed projects.


Responsibilities:

1.Conduct independent scholarly research and develop new methods and protocols
2. Participate in project planning, recording and evaluation of data
3. Acquire technical, lab management and grant writing skills
4. Participate in seminars, lectures, poster sessions and presentation at national meetings
5. Supervise junior lab members
6. Assist with other research projects


Qualifications/Preferred Skillsets:

This job is open to those seeking first or second post-docs., scientist or research associate positions. Preference also given to post-docs eligible for K99/R00 awards and those seeking future independent academic careers. PhD with a publication record strongly encouraged.
-
Requirements:
-A terminal degree PhD, MD, DVM, etc.
-According to the CMS (Centers for Medicaid and Medicare Services) a copy of diploma or transcript is required as proof of academic achievement for all non-laboratory personnel performing non-waived POC testing

-

To Apply Visit: https://career4.successfactors.com/sfcareer/jobreqcareer?jobId=82132&company=C0000169453P


Related Jobs